Lobe Sciences Ltd. (CSE:LOBE)

Revenue by Segment

Financials in millions CAD. Fiscal year is September - August.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021	Aug 31, 2020
Biopharmaceutical Development of New Medicines	136.21K	-
Total	136.21K	-

Revenue by Geography

Financials in millions CAD. Fiscal year is September - August.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021	Aug 31, 2020	Aug 31, 2019	Aug 31, 2018
Canada	136.21K	840.53K				773.79K	567.43K
Canada Growth	-83.80%	-				36.37%	-
Total	136.21K	840.53K				773.79K	567.43K
Total Growth	-83.80%	-				36.37%	-

Data Source: S&P Global Market Intelligence Last updated: Feb 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 28, 2026

Data Sources Report a data error